“In addition to presentations from thought leaders about Botanix programs, the Company also met with multiple industry partners to present an update on the progress of Botanix’s late stage clinical programs, BTX 1503 for acne and BTX 1204 for atopic dermatitis, as well the ongoing patient study for BTX 1308 for psoriasis. These meetings highlighted the interest of pharmaceutical companies and investors in the comparative data recently released by Botanix which demonstrated the superior drug delivery that the Company’s Permetrex technology enables.”
just wow.
Ann: Opinion Leaders Present Botanix Data at AAD 2019, page-6
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.3¢ |
Change
0.008(2.38%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $624.4K | 1.958M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 440962 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 515755 | 15 |
View Market Depth
| Last trade - 13.40pm 22/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
